Clinical Trial Sponsors (drug pipelines)
Regulated market (drugs@fda application holders) + trial-register participation (clinicaltrials.gov, eu ctis) + standards-body membership (cdisc). The Kin Score Market layer reads each provider in its market: who it integrates with, how deep those integrations go, and where the market publishes its own structure. Methodology.
Where this market publishes its structure
- ClinicalTrials.gov API v2 (interventional, started >= 2021, industry lead sponsor or collaborator) machine-readable, 43,972 studies / 10,267 industry names; participation only; 459 linked
- Drugs@FDA (openFDA drug/drugsfda bulk download; sponsor_name = application holder) machine-readable, 29,404 applications / 2,253 holders; names only; 36 linked; one certified product per application type
- EU CTIS public search (euclinicaltrials.eu/ctis-public-api/search, the page's own public JSON) machine-readable, 12,681 trials (10,000-row cap per query, read newest + oldest); 1,802 pharmaceutical-company sponsors; 158 linked
- CDISC member search (cdisc.org/members/search + public /company/ page website) machine-readable, 390 members, 374 with website; 34 linked by domain + name; the given URL /membership/member-list returns 404
Own = declares at least one integration itself; covered = visible only because an aggregator, standards body, regulator or partner contract names it; distribution-only = listed only on cloud marketplaces it sells through, a channel reported beside, never counted as its own declared integrations; undeclared = nothing we can read, so no number; declares_compatibility = providers with a `compatible` shape vote, report only (kin, 2026-10-13): never counted as own, never in depth or position.
Taxonomy how this market maps onto apis.io
Derived 2026-10-22 from the 55 providers in this market we could resolve in the catalog. The percentage is the share of those providers carrying each one; it describes the market, not the tag or industry. Tag groups have no page of their own yet, so they are listed unlinked.
| Tags | Pharmaceuticals 71%, Healthcare 65%, Life Sciences 64%, Biotechnology 55%, Clinical Trials 40%, Oncology 24% |
|---|---|
| Tag groups | Healthcare 96%, Health 25% |
| Industries | Biotechnology & Drug Discovery 80%, Pharmaceutical 76%, Healthcare 71%, Life Sciences 64%, Digital Health & Telehealth 33% |
share of resolved cohort carrying it; tags >=0.20 & >=3 members (max 12, junk dropped), tag_groups >=0.20 (cooccurrence, non-cross-cutting; max 8), industries >=0.20 (max 6), areas >=0.10 (max 6; areas are keyword-matched and sparse), capabilities L1 >=0.20 (max 8); derive-market-taxonomy.py
Leaders by position (provisional)
Provisional: grouped by position, depth compared within a position only. Distribution (cloud marketplaces) and iPaaS bridges are counted beside position, never inside it. Unknown-builder listings are left out of position shares and counted here.
undeclared 55 · declares nothing we can read: no number
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| A2 Biotherapeutics | undeclared | - | - | - | - | - | |
| AbbVie | undeclared | - | - | - | - | - | |
| Abcuro | undeclared | - | - | - | - | - | |
| ADARx Pharmaceuticals | undeclared | - | - | - | - | - | |
| ADC Therapeutics | undeclared | - | - | - | - | - | |
| AiCure | undeclared | - | - | - | - | - | |
| Alloplex Biotherapeutics | undeclared | - | - | - | - | - | |
| Amgen | undeclared | - | - | - | - | - | |
| Apogee Therapeutics | undeclared | - | - | - | - | - | |
| AstraZeneca | undeclared | - | - | - | - | - | |
| Bayer | undeclared | - | - | - | - | - | |
| Beacon Biosignals | undeclared | - | - | - | - | - | |
| Biogen | undeclared | - | - | - | - | - | |
| Bristol Myers Squibb | undeclared | - | - | - | - | - | |
| Celgene | undeclared | - | - | - | - | - | |
| Chimerix | undeclared | - | - | - | - | - | |
| CIONIC | undeclared | - | - | - | - | - | |
| Denali Therapeutics | undeclared | - | - | - | - | - | |
| Eli Lilly | undeclared | - | - | - | - | - | |
| Endeavor BioMedicines | undeclared | - | - | - | - | - | |
| Engrail Therapeutics | undeclared | - | - | - | - | - | |
| Epizyme | undeclared | - | - | - | - | - | |
| Genentech | undeclared | - | - | - | - | - | |
| Gilead Sciences | undeclared | - | - | - | - | - | |
| Hospira | undeclared | - | - | - | - | - | |
| Huma | undeclared | - | - | - | - | - | |
| Insmed | undeclared | - | - | - | - | - | |
| Intersect ENT | undeclared | - | - | - | - | - | |
| JenaValve Technology | undeclared | - | - | - | - | - | |
| Johnson & Johnson | undeclared | - | - | - | - | - | |
| Life Biosciences | undeclared | - | - | - | - | - | |
| Merck | undeclared | - | - | - | - | - | |
| Neomorph | undeclared | - | - | - | - | - | |
| Neurelis | undeclared | - | - | - | - | - | |
| NeuroTherapia | undeclared | - | - | - | - | - | |
| Novartis | undeclared | - | - | - | - | - | |
| Novo Nordisk | undeclared | - | - | - | - | - | |
| Orapharma | undeclared | - | - | - | - | - | |
| Organon | undeclared | - | - | - | - | - | |
| Pfizer | undeclared | - | - | - | - | - | |
| ReCode Therapeutics | undeclared | - | - | - | - | - | |
| Regeneron | undeclared | - | - | - | - | - | |
| Revolution Medicines | undeclared | - | - | - | - | - | |
| Sanofi | undeclared | - | - | - | - | - | |
| Schrödinger | undeclared | - | - | - | - | - | |
| Scimar | undeclared | - | - | - | - | - | |
| Sibel Health | undeclared | - | - | - | - | - | |
| Strata Oncology | undeclared | - | - | - | - | - | |
| Sunshine Lake Pharma | undeclared | - | - | - | - | - | |
| Tune Therapeutics | undeclared | - | - | - | - | - | |
| Vera Therapeutics | undeclared | - | - | - | - | - | |
| Verastem | undeclared | - | - | - | - | - | |
| Verily Life Sciences | undeclared | - | - | - | - | - | |
| Viatris | undeclared | - | - | - | - | - | |
| Zurex Pharma | undeclared | - | - | - | - | - |
Generated 2026-10-22 from API Evangelist's own files; nothing on this page is a model's judgement. Provisional and unweighted; not part of the Kin Score composite or agent readiness. Read the Market layer methodology. Disagree with an edge? Every edge cites its evidence and can be corrected through the normal correction path.